Final Survival Outcomes With Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC: RELAY Japanese Subset by Makoto Nishio, MD, PhD, Takashi Seto, MD, PhD, Martin Reck, PhD, Edward B. Garon, MD, Kazuto Nishio, MD, PhD, Kazuo Kasahara, MD, PhD, Kazumi Nishino, MD, PhD, Miyako Satouchi, MD, PhD, Kiyotaka Yoh, MD, Hidetoshi Hayashi, MD, PhD, Kazuko Sakai, PhD, Sotaro Enatsu, MD, PhD, Bente Frimodt-Møller, MSc, Tomoko Matsui, Sunoj Chacko Varughese, MSc, Michelle Carlsen, MS, Carla Visseren-Grul, MD, Kazuhiko Nakagawa, MD, PhD

Get full text